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Abstract
AIM
To systematically review reports on deceased-donor-lobar 
lung transplantation (ddLLTx) and uniformly describe size 
SYSTEMATIC REVIEWS
70 February 24, 2017|Volume 7|Issue 1|WJT|www.wjgnet.com
Lobar lung transplantation from deceased donors: A 
systematic review
World J Transplant  2017 February 24; 7(1): 70-80
ISSN 2220-3230 (online)
Submit a Manuscript: http://www.wjgnet.com/esps/
DOI: 10.5500/wjt.v7.i1.70
World Journal of 
TransplantationW J T
matching using the donor-to-recipient predicted-total 
lung-capacity (pTLC) ratio. 
METHODS
We set out to systematically review reports on ddLLTx 
and uniformly describe size matching using the donor-
to-recipient pTLC ratio and to summarize reported one-
year survival data of ddLLTx and conventional-LTx. We 
searched in PubMed, CINAHL via  EBSCO, Cochrane 
Database of Systematic Reviews via  Wiley (CDSR), 
Database of Abstracts of Reviews of Effects via  Wiley 
(DARE), Cochrane Central Register of Controlled Trials 
via  Wiley (CENTRAL), Scopus (which includes EMBASE 
abstracts), and Web of Science for original reports on 
ddLLTx. 
RESULTS 
Nine observational cohort studies reporting on 301 ddLLTx 
met our inclusion criteria for systematic review of size 
matching, and eight for describing one-year-survival. The 
ddLLTx-group was often characterized by high acuity; 
however there was heterogeneity in transplant indications 
and pre-operative characteristics between studies. Data 
to calculate the pTLC ratio was available for 242 ddLLTx 
(80%). The mean pTLCratio before lobar resection was 
1.25 ± 0.3 and the transplanted pTLCratio after lobar 
resection was 0.76 ± 0.2. One-year survival in the ddLLTx-
group ranged from 50%-100%, compared to 72%-88% 
in the conventional-LTx group. In the largest study ddLLTx 
(n  = 138) was associated with a lower one-year-survival 
compared to conventional-LTx (n  = 539) (65.1% vs 
84.1%, P  < 0.001). 
CONCLUSION
Further investigations of optimal donor-to-recipient size 
matching parameters for ddLLTx could improve outcomes 
of this important surgical option.
Key words: Lobar lung transplantation from deceased 
donors; Cadaveric lobar lung transplantation; Lung size 
matching; Primary graft dysfunction; Survival
© The Author(s) 2017. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: Deceased-donor-lobar lung transplantation 
(ddLLTx) is an important and so far underutilized surgical 
option for lung transplant candidates with small chest 
cavities. It is only performed at a few specialized centers 
and frequently performed in high urgency cases. Outcome 
is acuity-driven and is expected to improve as more 
elective cases are done. The size matching decision for 
ddLLTx is complex and based on varying parameters. 
Systematically using the predicted Total Lung Capacity 
ratio as the size matching tool could help to identify 
sizing thresholds to maximize the risk/benefit balance for 
ddLLTx. 
Eberlein M, Reed RM, Chahla M, Bolukbas S, Blevins A, Van 
Raemdonck D, Stanzi A, Inci I, Marasco S, Shigemura N, Aigner 
C, Deuse T. Lobar lung transplantation from deceased donors: 
A systematic review. World J Transplant 2017; 7(1): 70-80 
Available from: URL: http://www.wjgnet.com/2220-3230/full/
v7/i1/70.htm  DOI: http://dx.doi.org/10.5500/wjt.v7.i1.70
INTRODUCTION
Lung transplantation (LTx) is an established therapy 
for appropriately selected patients suffering from end-
stage lung disease. Since the implementation of the 
Lung Allocation Scoring (LAS) system, characteristics 
of candidates on the wait list have changed to include 
a sicker group of patients with a greater proportion of 
restrictive lung diseases (LAS diagnoses group D)[1,2]. As 
a consequence, wait-list mortality rates are again rising 
despite higher wait-list transplant rates compared to the 
pre-LAS era[3]. Potential LTx-recipients with short stature 
and small thoracic cavities have longer waiting times 
on the LTx list, as donor lungs considered to be size-
appropriate are particularly limited[3,4]. This often affects 
patients with cystic fibrosis and pulmonary fibrosis[4]. 
In both groups, LTx can become an urgent issue when 
significant disease exacerbations occur, and in this 
setting in particular patients are at high risk for wait 
list mortality. Higher acuity at the time of LTx is in turn 
associated with decreased survival[5]. 
Three operative solutions exist to increase the 
utilization of available deceased donors for patients with 
small chest cavities[6-8]. These include: (1) deceased lobar 
lung transplant (ddLLTx)[6,8]; (2) split lung transplant (a 
form of ddLLTx, where the left lung allograft is divided 
and then each resulting lobe is implanted into the two 
hemithoraces)[9]; and (3) peripheral atypical resection. 
ddLLTx was first described by Bisson et al[8] in 1994. 
Subsequently, several single center reports on ddLLTx 
have been published[6,7,9-16].
The best size-matching parameter remains debatable. 
Chest X-ray parameters, calculation of the ratio between 
donor and recipient heights, calculation of the ratio of 
predicted total lung capacity (pTLC) between donor and 
recipient (pTLCratio) and estimation based on visual 
inspection in the operating room are commonly used 
strategies[17]. Amongst these the pTLCratio has the largest 
evidence base to support its use[17-30].
Therefore, we set out to systematically review reports 
on ddLLTx with the aim to describe the size matching 
between donor and recipient uniformly using the pTL-
Cratio[31-33]. Specifically we intended to compare the 
pTLCratio that would have occurred using the entire donor 
lungs (pTLCratioFull) to the pTLCratio that was transplanted 
via the lobar transplantation (pTLCratioLobar). The second 
objective was to perform a systematic review and meta-
analysis of one-year survival after ddLLTx. 
MATERIALS AND METHODS
Data sources
A health sciences librarian ran extensive literature searches 
in PubMed, CINAHL via Ebsco, Cochrane Database of 
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Systematic Reviews via Wiley (CDSR), Database of 
Abstracts of Reviews of Effects via Wiley (DARE), Cochrane 
Central Register of Controlled Trials via Wiley (CENTRAL), 
Scopus (which includes EMBASE abstracts), and Web 
of Science. No filters for date, language, or any other 
parameter were used. The PubMed strategy described 
below was modified as needed for use in other electronic 
databases. Full search strategies are available upon 
request. 
The search strategy was for PubMed: (((((“Lung 
Transplantation”[Mesh] OR lung transplant*[Text Word] 
OR lung graft*[text word])) OR ((“Tissue and Organ 
Procurement”[Mesh] OR “Tissue Donors”[Mesh] OR “Organ 
Transplantation”[Mesh] OR organ procurement*[text 
word] OR tissue procurement*[text word] OR tissue 
donor*[text word] OR organ donor*[text word] OR organ 
transplant*[text word]) AND (Lung[Mesh] OR Lung[text 
word] OR Lungs[text word])))) AND ((lobar[text word] 
OR lobe*[text word]))) AND ((“Cadaver”[Mesh] OR 
Cadaver*[text word] OR Dead[text word] OR Nonliving[text 
word] OR Non-living[text word])). 
Study selection criteria
For an identified study to be included in the systematic 
review it had to: (1) involve human participants; (2) 
have full text available in English; and (3) report on 
recipients of ddLLTx. For an identified study to be 
included in the meta-analysis it had to meet the following 
additional criteria: one year survival data is available for: 
(1) a conventional lung transplant cohort (either in same 
study or from a contemporary publication from the same 
center); and (2) a ddLLTx cohort. When overlapping 
data, i.e., several publications from same center, study 
selection favored most recent data. The corresponding 
authors of the studies selected for inclusion in the 
systematic analysis were contacted to seek unpublished 
updated center data.
Study quality assessment
The methodological quality of the selected studies 
was evaluated using criteria from the United States 
Preventative Services Task Force. 
Data extraction
Data extracted included author name, year of publication, 
location of center, number of patients in ddLLTx cohort, 
number of patients in conventional-LTx cohort, study-
years, indication for transplantation and acuity at time 
of transplant. Outcome data extracted included rate of 
primary graft dysfunction (PGD), ICU and hospital length 
of stay (LOS), FEV1(%-predicted) at 6 mo and peak 
FEV1, survival at 1 year and 5 years.
Assessment of donor to recipient size matching
The parameter(s) used for the size matching were 
extracted for each study. For all studies that did not 
report recipient pTLC (pTLCrecipient), full donor pTLC 
(pTLCdonorFull) and donor pTLC after lobar resection 
(pTLCdonorLobar) the study authors were contacted and 
asked to provide: recipient age, height and sex (to 
calculate pTLCrecipient[18]); donor age, height and sex (to 
calculate pTLCdonorFull[18]) and information on donor lobes 
transplanted [to calculate pTLCdonorLobar = (pTLCdonorFull)
× (number donor lung segments transplanted/19)] for 
each donor and recipient pair. From this the pTLCratio that 
would have occurred using the entire donor lungs was 
calculated as pTLCratioFull = pTLCdonorFull/pTLCrecipient. 
The pTLC ratio that was actually transplanted via the 
lobar transplantation was calculated as pTLCratioLobar = 
pTLCdonorLobar/pTLCrecipient, Figure 1.
Definitions of primary and secondary outcomes
The primary outcome of interest was one-year-survival. 
Secondary outcomes were occurrence of PGD, ICU and 
hospital LOS, FEV1 (6 mo and peak) and 5-year survival. 
Statistical analysis
We expressed pTLCratioFull and pTLCratioLobar as means ± 
standard deviation for the entire cohort and stratified by 
transplant indication and transplant center. We assessed 
for differences in mean pTLCratioFull and pTLCratioLobar 
between transplant indications and centers by one-way 
ANOVA analysis of variance, with bonferroni adjustment 
for multiple comparisons. We extracted dichotomous 
data for one-year-survival form all studies reporting 
number of patients with events and total participants. 
We performed a meta-analysis and pooled the one-
year-mortality data to calculate relative risks (risk ratios, 
RRs) with 95% confidence interval (CI). We used the 
statistic of I2 to test for the heterogeneity, with I2 < 25%, 
25%-75% and > 75% to represent low, moderate and 
high degree of inconsistency, respectively. In analyses, 
if the heterogeneity was low then we used a fixed-
effect model, or else applied the random-effect model. 
We performed a sensitivity analysis, in which a study 
was removed at a time while the rest was analyzed, 
to evaluate whether the results could have markedly 
been affected by that single study. We used Egger’s 
linear regression test to find a potential publication bias. 
All analyses were performed with Stata (Version10.0, 
Stata Corporation, College Station, TX, United States). 
A 2-tailed P value of less than 0.05 was considered 
statistically significant. 
RESULTS
Search results
Our search identified 155 unique citations. Of these, 32 
abstracts and 18 full-text publications were assessed 
(Figure 2). Nine studies fulfilled our inclusion criteria 
for final review[6,7,10-16] (Table 1). Reviewer agreement 
on selection of abstracts was 100% (K = 1.0) and on 
inclusion of articles for the final review it was 100% (K = 
1.0).
Study range and characteristics
All nine reports were single center retrospective cohort 
studies. Seven reports originated in Europe[6,7,10,12,14-16], 
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Indication for transplant and acuity
In the nine studies including 301 ddLLTx, the indications 
were available in eight studies (295 ddLLTx) and were 
predominantly cystic fibrosis (39%) and interstitial 
lung diseases (35%) (Figure 3). Six of the nine studies 
qualified the acuity of ddLLTx and these were often 
characterized by high acuity (Table 1).
Donor to recipient size matching
The size matching parameter used was the pTLCratio 
in five of nine studies, often in combination with 
visual inspection of fully inflated allograft and recipient 
chest cavity size in the operating room. Donor and 
recipient height and CXR characteristics were used in 
2 studies (Table 2). Two studies reported pTLCdonorFull, 
pTLCdonorLobar and pLTCrecipient[6,11]. Data to calculate 
these parameters were provided for five additional 
studies[7,12,13,15,16] and pTLCdonorFull, pTLCdonorLobar 
and pLTCrecipient was then available for 242 of 301 
donor-recipient pairs of ddLLTx (Figure 1). The mean 
pTLCdonorFull was 6.42 ± 1.0 L and after lobar resections 
was reduced to pTLCdonorLobar 3.83 ± 0.8 L. The mean 
pLTCrecipient was 5.27 ± 1.0 L. The mean pTLCratioFull 
was 1.25 ± 0.3 and was reduced to a mean pTLCratioLobar 
0.76 ± 0.2. Stratified by transplant indication, the 
interstitial lung diseases group had the lowest mean 
pTLCratioFull (1.12 ± 0.03), which was significantly lower 
than COPD (1.37 ± 0.3) and CF (1.33 ± 0.3) (Figure 4). 
After lobar resections the transplanted mean pTLCratioLobar 
was also the lowest in interstitial lung diseases group (0.70 
± 0.1) and significantly lower than COPD (0.87 ± 0.3) 
and CF (0.79 ± 0.2) (Figure 4). Stratified by transplant 
centers the pTLCratioFull ranged from 1.15 ± 0.4 to 1.68 
± 0.4 (Figure 5). The transplanted pTLCratioLobar ranged 
between transplant centers from 0.69 ± 0.1 to 0.94 ± 0.3 
one in Australia[11], and one in North America[13]. The study 
period ranged from 1988-2012. Four centers reported on 
fewer than 10 recipients of ddLLTx, two had 20-35 ddLLTx 
recipients, and two reported 50 or more ddLLTx cases.
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Figure 1  The parameter(s) used for the size matching were extracted for each study. For all studies that did not report recipient pTLC (pTLCrecipient), full donor 
pTLC (pTLCdonorFull) and donor pTLC after lobar resection (pTLCdonorLobar) the study authors were contacted and asked to provide: Recipient age, height and 
sex (to calculate pTLCrecipient); donor age, height and sex (to calculate pTLCdonorFull) and information on donor lobes transplanted [to calculate pTLCdonorLobar 
= (pTLCdonorFull) × (number donor lung segments transplanted/19)] for each donor and recipient pair. From this the pTLCratio that would have occurred using the 
entire donor lungs was calculated as pTLCratioFull = pTLCdonorFull/pTLCrecipient. The pTLC ratio that was actually transplanted via the lobar transplantation was 
calculated as pTLCratioLobar = pTLCdonorLobar/pTLCrecipient. ddLLTx: Deceased-donor-lobar lung transplantation.
Citations identified and screened: 311
  PubMed: 89
  Scopus: 121
  Web of Science: 67
  CDSR: 0
  CINAHL: 0
  CENTRAL: 0
  DARE: 0
  Hand Searched References: 34
Unique citations: 155
Excluded based on eligibility 
criteria after title and/or 
abstract review: 136
Selected for full-text 
Review: 19
Excluded for systematic review
  Updated center data: 3
  Only living donor lobar transplant 
reported: 7
Selected for systematic 
review: 9
Excluded for meta-analysis:
  No conventional lung transplant 
comparison cohort: 1
Selected for 
meta-analysis: 8
Duplicates: 156
Figure 2  PRISMA diagram detailing study selection.
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(Figure 5). 
Primary outcome: One year survival
Nine studies (301 patients) provided data on one-year 
survival after ddLLTx (Table 3). One-year survival in the 
ddLLTx groups ranged from 50%-100%. We identified 
survival information for a conventional-LTx comparison 
group within the same institution for eight studies. 
One-year survival was 72%-88% in the conventional-
LTx groups, which was not statistically different within 
each individual study, with the exception of the largest 
study, where ddLLTx was associated with a higher risk 
of mortality (65.1% vs 84.1% one-year survival, P < 
0.001)[15]. 
In pooled analysis of unadjusted data from eight 
studies, ddLLTx-recipients (n = 284) had a relative risk of 
one-year mortality of 1.85 (95%CI: 1.52-2.25, P < 0.001) 
compared with conventional-LTx-recipients (n = 2777) 
(Figure 6). There was low heterogeneity as indicated 
by an I2 of 0% (P = 0.47). In an analysis for possible 
publication bias by performing a linear regression of the 
standard normal deviate against precision (Egger test) 
showed that the intercepts did significantly deviate from 
zero (P = 0.007, for one-year-survival), indicating the 
presence of publication bias. Visual inspection of the 
funnel plot showed asymmetry (Figure 7). This also 
indicated the presence of publication bias, limiting the 
interpretation of the meta-analysis. 
Secondary outcomes
Five studies described the occurrence of primary graft 
dysfunction (PGD) and described rates ranging between 
13%-56% in ddLLTx (Table 3). One study reported ddLLTx 
Table 2  Size matching parameters and characteristics
Table 1  Study characteristics
Author Year Country Center Time Nr Indication/diagnosis Acuity
CF IPF IPAH COPD Other
Couetil 1997 France Paris 1993-1994 7 3 1 2 1 - Not reported
Espinosa 2010 Spain Reina Sofia 2003-2009 6 - - - - - 2 ICU, 
2 Hosp, 
2 Outpatient
Deuse 2011 Germany Hamburg 2009-2012 71 2 5 - - - 1 ECMO
Marasco 2012 Australia Alfred 1990-2012 271 6 5 - 4 12 Not reported
Inci 2012 Swiss Zurich 2000-2012 23 10 8 - 3 2 3 ECMO, 1 MV,
Shigemura 2013 United States UPMC 2010-2012 351 4 17 - - 14 7 ECMO, 9 MV, LAS 72-94
Mitilian 2013 France Foch 1988-2012 50 35 7 - 3 5 2 ECMO
Aigner 2014 Austria Vienna 2001-2012 1381 48 46 8 16 20 27 MV, 18 ECMO
Stanzi 2014 Belgium Leuven 2005-2012 8 8 - - - - All outpatients
1Updated data provided. Nr: Number; CF: Cystic fibrosis; IPF: Idiopathic pulmonary fibrosis; IPAH: Idiopathic pulmonary arterial hypertension; OB: 
Obliterative bronchiolitis; COPD: Chronic obstructive pulmonary disease; ECMO: Extracorporeal membrane oxygenation; ICU: Intensive care unit; Hosp: 
Hospitalized; MV: Mechanical ventilation; LAS: Lung allocation score.
Center Size matching parameter pTLC donor (full) pTLC donor (lobar) pTLC recipient pTLCratio (full) pTLCratio (lobar)
Paris pTLCratio 6.91 ± 0.7 3.11 ± 0.3 4.28 ± 1.1 1.69 ± 0.4 0.76 ± 0.5
Reina Sofia Not reported Not provided Not provided Not provided Not provided Not provided
Hamburg1 pTLCratio 6.96 ± 1.2 3.64 ± 0.7 5.27 ± 1.0 1.35 ± 0.3 0.69 ± 0.1
Alfred1 pTLCratio, CXR 6.82 ± 1.2 4.81 ± 1.1 5.12 ± 1.4 1.44 ± 0.5 0.94 ± 0.3
Zurich1 Visual inspection, height 7.21 ± 0.8 4.45 ± 0.7 5.04 ± 0.9 1.48 ± 0.4 0.90 ± 0.2
UPMC1 Height, CXR, visual inspection 6.28 ± 0.7 3.76 ± 0.7 5.22 ± 0.8 1.22 ± 0.9 0.73 ± 0.5
Foch pTLCratio, visual inspection Not provided Not provided Not provided 1.65 Not provided
Vienna1 pTLCratio, visual inspection 6.19 ± 1.1 3.80 ± 0.9 5.45 ± 1.0 1.15 ± 0.2 0.70 ± 0.1
Leuven1 Visual inspection, height 6.70 ± 1.2 4.11 ± 0.3 4.42 ± 0.4 1.52 ± 0.4 0.93 ± 0.3
1Centers provided additional size matching data for this systematic review. pTLC: Predicted total lung capacity; CXR: Chest X-ray. 
CF 39%
IPF 35%
Other 12%
COPD 9%
IPAH
 5%
Figure 3  Pie chart of transplant indications. IPAH: Idiopathic pulmonary 
arterial hypertension; COPD: Chronic obstructive pulmonary disease;IPF: 
Idiopathic pulmonary fibrosis; CF: Cystic fibrosis.
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PGD rates compared to conventional-LTx. At 48 h, PGD 
grade 3 rates were 25% in ddLLTx (n = 8), compared to 9% 
in the conventional-LTx (n = 66) group[16]; this difference, 
however, was not statistically significant in that study. Three 
studies reported on postoperative ECMO needs, which 
ranged from 20%-36% in the ddLLTx groups[13-15]. Four 
studies reported on ICU LOS. This ranged from 12 to 27 
d in ddLLTx, compared to 4-6 d in conventional-LTx, Table 
3. Five studies reported on FEV1 in the post-ddLLTx period, 
Table 4. At 3-6 mo following ddLLTx FEV1 (%-predicted) 
ranged from 52.6%-75.3%. Peak FEV1 (%-predicted) 
following ddLLTX ranged from 67.3%-85.2%. Only one 
study compared FEV1 (%-predicted) between ddLLTx (n = 
8) and conventional-LTx (n = 66) cohorts[16]. In that study, 
at 3 mo ddLLTx FEV1 (%-predicted) was 64.5%, compared 
to 76% (P-value non-significant) in conventional-LTx 
and peak FEV1 (%-predicted) was 80.5% and 99% 
(P-value non-significant) for the respective cohorts[16]. 
Two studies reported on the correlation between FEV1(%-
predicted) and the transplanted pTLCratio (= pTLCratioLobar) 
following ddLLTx and both studies found a significant 
correlation between the size of the transplanted lungs 
and FEV1(%predicted), Table 4. Four studies reported 
on 5 year survival following ddLLTx and this ranged 
from 37.5%-54.9%, compared to 51%-69.9% in the 
conventional-LTx groups, Table 3[11,12,14,15]. Five-year-
survival was not statistically different within each individual 
study, with the exception of the largest study, where 
ddLLTx was associated with a higher risk of mortality 
(54.9% vs 69.9% five-year survival, P < 0.001)[15]. 
DISCUSSION
The technique of deceased donor lobar lung trans-
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pTLCratioLobar (one-way-anova P-value < 0.05) of pairwise comparisons between transplant indications, after Bonferroni adjustment for multiple comparisons.
1.151,2,4,6 
± 0.4
1.485,6 
± 0.4
0.708,11 
± 0.1
0.9011,12 
± 0.2
Figure 5  Donor to recipient size matching based on the donor to recipient predicted total lung capacity ratio, stratified by transplant center. See figure legend 
3 for further details. 1,2,3,4,5,6Indicate a significant difference in pTLCratioFull (one-way-anova P-value < 0.05) of pairwise comparisons between transplant centers, after 
Bonferroni adjustment for multiple comparisons; 7,8,9,10,11,12Indicate a significant difference in pTLCratioLobar (one-way-anova P-value < 0.05) of pairwise comparisons 
between transplant centers, after Bonferroni adjustment for multiple comparisons. pTLC: Predicted total lung capacity.
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plantation (ddLLTx) is an important surgical option for 
LTx-candidates with small chest cavities and adds to our 
armamentarium of LTx techniques. The lung is a special 
organ that allows parenchyma resections to reduce its 
size without necessarily compromising the functionality 
of the remaining tissue. Amongst other solid organs, this 
remarkable feature is only shared by the liver, not by 
the heart or the kidneys and split liver transplants have 
already been established as a reliable tool to increase 
the donor pool for children[34]. After all, the anatomical 
organization of the graft and the number of individual 
lobes transplanted should be less of a concern than 
the total amount of lung parenchyma provided for the 
recipient.
Lobectomies are straightforward procedures, but 
are still rarely performed in the context of LTx. However 
lobectomies add to the surgical complexity of the LTx 
operation and may thus prolong the operative time. 
More importantly, when performed on the back-table, 
cooling may be impaired and the graft is exposed to 
warm ischemic time. These disadvantages need to 
be weighed against the advantages of significantly 
increasing the potential donor pool and reducing waiting 
times and waiting list mortality in LTx-candidates with 
small chest cavities[3]. Because prolonged waiting times 
often correlate with patient deconditioning, timely 
transplantation may also reduce the procedural risk 
for some patients. Differences in surgical strategies 
among centers include the preferred choice of lobes 
transplanted. Isolated lower and upper lobe transplants 
carry the fundamental advantage of not creating a 
bronchial stump as does bi-lobar transplantation of right 
Table 3  Outcomes of deceased donor lobar lung transplantation compared to conventional lung transplant within the same center
Center Comparison
Group with CLTx 
(number, diagnosis)
PGD (grade)
PostOP-ECMO
ICU LOS (d) Hospital LOS
(d)
Survival 1 year Survival 5 years
Paris No Not reported Not reported Not reported ddLLTx: 86% Not reported
Reina Sofia Yes (149 - mixed)1 Not reported Not reported Not reported ddLLTx: 50%, CLTx: 72%1 Not reported
Hamburg Yes (28 - mixed)4 Not reported Not reported Not reported ddLLTx: 85%, CLTx: 72%4 Not reported
Alfred Yes (329 - mixed) ddLLTx: 56% ≥ 
PGD (2)
LLT: 12; CLTx: 
4
ddLLTx: 30 
CLTx: 21
ddLLTx: 81%, CLTx: 84% (P = 
0.115)
ddLLTx: 52%5, CLTx: 37.5%5
(P = 0.115)
Zurich Yes (219 - mixed) ddLLTx: 13% 
PGD (not spec.)
Not reported Not reported ddLLTx: 82%; CLTx: 88% (P = 
0.56)
ddLLTx: 64%; CLTx: 69% (P = 
0.56)
UPMC Yes (691 - mixed)2,
Yes (65 - high LAS)3
ddLLTx:
36% ECMO
Not reported Not reported ddLLTx: 76%; CLTx: 83%1; (high 
LAS): 72%2
Not reported
Foch Yes (445 - mixed) ddLLTx: 54% ≥
PGD (1)
20% ECMO
ddLLTx: 17 ddLLTx: 43 ddLLTx: 60%, CLTx: 78% (NS) ddLLTx: 46%, CLTx: 51% (NS)
Vienna Yes (778 - mixed) ddLLTx: 44%≥
PGD1
32% ECMO
ddLLTx: 17;
CLTx: 6
ddLLTx: 33.5 
CLTx: 22
ddLLTx: 65.1; CLTx: 84.8% (P < 
0.001)
ddLLTx: 54.9% 
CLTx: 69.9%
(P < 0.001)
Leuven Yes (66 - all CF) ddLLTx: 25% 
PGD (3) at 48 h 
vs CLTx: 9%
ddLLTx: 12 
CLTx: 5
ddLLTx: 37 
CLTx: 24
ddLLTx: 100%; CLTx: 88.4% 
(NS)
Not reported
1,2,3From contemporary, but separate reports from same transplant center as the ddLLTx group; 4Provided by center; 5Estimated from Kaplan Meier survival 
curve. PGD: Primary graft dysfunction; ECMO: Extracorporeal membrane oxygenation; ICU: Intensive care unit; LOS: Length of stay; NS: Not statistically 
significantly different; ddLLTx: Donor lobar lung transplantation; CLTx: Compared to conventional lung transplant. 
Study
Reina Sofia
Hamburg
Alfred
Zurich
UPMC
Foch
Vienna
Leuven
Overall (95%CI)
1.77 (0.77, 4.11)              3.8
0.41 (0.07, 2.58)              5.3
1.84 (0.98, 3.46)              9.3
1.46 (0.56, 3.83)              5.7
1.42 (0.69, 2.90)              9.5
1.82 (1.24, 2.66)            22.9
2.29 (1.73, 3.04)            41.2
0.44 (0.03, 6.96)              2.3
Risk ratio
(95%CI)
% weight
1.85 (1.52, 2.25) P  < 0.001
0.5     1         2.5     5
Risk ratio
Figure 6  Forest plot for pooled analysis of 1 year 
survival comparing deceased donor lobar lung 
transplantation to conventional lung transplant. 
Vertical line is the “no difference” point in 1 year 
mortality between dLLTx and CLTx cohorts. Horizontal 
lines are 95%CI. ■ = Relative Risk (RR) and the size 
of each square denotes the proportion of information 
provided by each trial. ◊ = pooled RR for all studies 
combined. dLLTx: Donor lobar Lung transplantation; 
CLTx: Conventional lung transplant.
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upper + middle or upper + lower lobes. Although there 
is a considerable size mismatch between the recipient 
main bronchus and a lobar graft bronchus, careful 
adjustment during surgery allows tension-free alignment 
in most of the cases. Airway complications have been 
described and in one study, anastomotic stenoses were 
reported to occur more frequently in ddLLTx than in 
full-size transplantation[7,10,11,14,16,35]. However, most 
airway complications were bronchial stenoses that were 
amenable for bronchoscopic treatment[14,35].
The size matching parameter utilized to make the 
decision to perform a ddLLTx varied between studies 
and some degree of surgeon-specific assessment based 
on visual inspection was repeatedly reported. However, 
among objective parameters, the pTLCratio was most 
frequently reported and offers the possibility to compare 
practices and results among centers. To our knowledge, 
this is the first study that uniformly analyzes size 
matching for ddLLTx based on the pTLCratio. 
Although all 9 centers reporting ddLLTx for down-
sizing have somewhat different patient populations and 
surgical philosophies, there were remarkable similarities. 
The mean recipient’s pTLCs were mostly reported at 
around 5 L, only in two reports (Paris and Leuven) 
the mean recipient pTLCs were in the 4-4.5 L range, 
reflecting a higher proportion of pediatric recipients. 
Although the decision to perform a ddLLTx was based 
on different sizing considerations, the down-sizing 
performed as reflected by the pTLCratioLobar was similar 
among centers and averaged at 0.76 ± 0.2. The general 
preference towards undersizing in the setting of fibrotic 
lung diseases[17,36] was also evident in this systematic 
review, where the interstitial lung diseases group had the 
lowest mean pTLCratioFull (1.12 ± 0.03) and after lobar 
resections the transplanted mean pTLCratioLobar was also 
the lowest in interstitial lung diseases group (0.70 ± 0.1) 
(Figure 4). 
In previous studies the pTLCratio was found to be an 
independent predictor of survival after LTx[21,22,25-28,37]. In 
an analysis of the SRTR database in the post-LAS era, 
the pTLCratio showed an independent and nonlinear 
association with one-year-survival after LTx, irrespective 
of LTx indication[27]. There was a declining risk of death 
with higher pTLCratio from 0.5 to about 1.3, where an 
inflection occurred with rising risk at pTLCratios > 1.3[27]. 
Furthermore, in an ancillary study to the Lung-Transplant-
Outcomes-Group, oversized allografts were associated 
with a decreased risk of PGD grade 3 after bilateral-LTx[36]. 
This association was most apparent in recipients with 
risk factors for PGD[38]. There are concerns that in the 
intra-operative and early post-LTx period, hemodynamic 
compromise can occur in the setting of a profoundly 
oversized allograft secondary to a compartment-
syndrome-like picture occurring after chest closure. Also, 
persistent atelectasis may hamper overall oxygenation 
and increase the risk for pulmonary infections. However in 
a single center study oversized allografts (mean pTLCratio 
1.18 ± 0.14, range 1.01-1.63), when compared with 
undersized allografts (mean pTLCratio 0.89 ± 0.09, range 
0.63-1.00), were not associated with an increase in post-
LTx complications. On the contrary, oversized allografts 
were associated with a shorter hospital LOS after LTx 
Table 4  Post-transplant FEV1 outcomes of deceased donor lobar Lung transplantation
Center (Nr of 
ddLLTx)
Comparison 
group (Nr)
FEV1 (%) 3-6 mo Peak FEV1 
(%)
Correlation to pTLCratio
Paris (7) No 6 mo: 62% 81% Not reported
Reina Sofia (6) No Not reported Not reported Not reported
Hamburg (3) No Not reported Not reported Not reported
Alfred (23) No 6 mo: 52.6% Not reported Yes
FEV1(%) at 3 mo correlates with pTLCratioLobar (r = 0.549, P = 0.028)
Zurich (23) No 6 mo: 75.3% 76.80% Yes
FEV1(%) at 3 mo correlates with pTLCratioLobar (r = 0.485, P = 0.04)
UPMC (25) No Not reported 85.20% Not reported
Foch (50) No 6 mo: 61.1% 67.30%
Vienna No Not reported Not reported Not reported
Leuven (6) Yes
CLTx (66)
3 mo:
ddLLTx: 64.5%
CLTx: 76%
ddLLTx: 80.5
CLTx: 99%
Not reported
ddLLTx: Donor lobar Lung transplantation; CLTx: Compared to conventional lung transplant.
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Figure 7  Funnel plot for assessment of publication bias in 1 year mortality 
results.
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and lower resource utilization[20]. These previous data 
linking the pTLCratio to important post-LTx outcomes 
could suggest that for severely oversized pTLCratioFull (in 
excess of > 1.4) a ddLLTx could be an important surgical 
option however should be performed only in special 
circumstances in cases with lower pTLCratioFull. 
The principal finding was that the ddLLTx-group 
appeared to have a higher risk for one-year mortality 
than the conventional-LTx-group. In the meta-analysis 
the ddLLTx and conventional-LTx-groups were unmatched 
and the outcomes were unadjusted for confounders. 
Furthermore, the Egger test and visual inspection of the 
funnel plot for the 1 year survival meta-analysis indicated 
the presence of publication bias. In terms of publication 
bias, an underreporting of unsuccessful ddLLTx cases 
is or appears more likely than an underreporting of 
superior outcomes of ddLLTx compared to conventional 
LTx. Because of the above issues, the results of the 
meta-analysis need to be interpreted with caution. The 
majority of the included single center studies showed 
no statistically significant survival difference, although 
most studies suggested a trend towards higher one-year 
mortality in the ddLLTx-group. The largest single center 
study, however, showed a significantly higher risk for one-
year mortality in the ddLLTx-group. Importantly, there 
are significant clinical differences between the ddLLTx 
and conventional-LTx-groups, which are not adjusted 
for in the pooled analysis. Because ddLLTx is more 
frequently used in very urgent cases to realize timely LTx, 
it is likely that the one-year-survival differences between 
ddLLTx and conventional-LTx groups are due to the high 
acuity of the ddLLTx-group. In the Vienna experience, 
for example, patients receiving ddLLTx were significantly 
more urgent and more frequently on mechanical 
ventilation or ECMO support pre-LTx[15]. The Pittsburgh 
experience also supports the notion of an acuity-driven 
mortality risk associated with ddLLTx. Only very urgent 
patients with LAS > 70 were considered as candidates 
for ddLLTx. This very high acuity ddLLTx group achieved 
a 76% one-year survival (n = 35)[13], which was similar 
to that of the high-LAS-cohort (LAS > 50) receiving 
full-sized lung transplants (72% one-year survival, n = 
108)[39]. Resource utilization following ddLLTx seems to 
reflect the pre-transplant high acuity of the recipients. In 
three studies reporting on postoperative ECMO needs, 
this ranged from 20-36% in the ddLLTx groups[13-15]. Four 
studies reported on ICU LOS and this ranged from 12 to 
27 d in ddLLTx, compared to 4-6 d in conventional-LTx 
(Table 3). It thus remains to be seen if elective ddLLTx in 
routine LTx-candidates achieves outcomes comparable to 
those of elective full-sized LTx. This is supported by the 
experience of the Leuven group, where a cohort of eight 
stable outpatient LTx-candidates with cystic fibrosis had 
a 100% one-year survival after ddLLTx[16]. Other centers 
also reported favorable results with ddLLTx in elective, 
non-urgent cases[40].
Our study has several limitations. All of the included 
reports were retrospective observational cohort studies. 
Although this study systematically analyzed size ma-
tching using the pTLCratio, data for its calculation was 
not available for all patients of the ddLLTx-cohort. 
Physiologically there a notable difference between a CF 
patient with short stature and a normal sized IPF patient 
with the exceptionally small chest cavity from the fibrotic 
lung disease. For this systematic review only aggregate 
data on outcomes was available and these two groups 
could not be analyzed separately. However the pTLC 
of the recipient would adequately reflect the “normal” 
chest cavity size of these two very different populations. 
Whereas using the actually measured total lung capacity 
or visual inspection of the chest cavities on imaging or in 
the operating room largely reflects the disease specific 
effects of the underlying lung diseases on the chest cavity 
size. However, such alterations in chest cavity size have 
been shown to be quickly reversible. Assessing chest 
cavity size via opto-electronic-plethysmography post-
LTx demonstrated that, irrespective of LTx-indication, 
the chest volume and the response to exercise was not 
different from normal controls[41]. In this systematic 
review 2 studies reported on donor and recipient pTLC 
and both studies used regression equation based on 
sex and height to derive pTLC[6,11]. Whereas for the 
calculations of donor and recipient pTLC done as part of 
this systematic review from data provided by the authors 
of five of the included studies[7,12,13,15,16] were based on age, 
sex and height[18]. While the latter approach accounts for 
the main determinants of lung size, the race effect on 
lung size remains unaccounted for with both approaches. 
The best regression equation to calculate pTLC is not 
defined, but computed tomography (CT) and CT-
volumetry is increasingly used to derive comprehensive 
and refined regression equations for pTLC[42]. There 
were wide variations in rates of PGD, likely in part due 
to variation in definitions, surveillance methods, and 
reporting. Despite between-institution variability, each 
individual institution reportedly treated ddLLTx and 
conventional-LTx cohorts similarly. The majority of the 
included reports originated in Europe[6,7,10,12,14-16] with 
only one originating from Australia[11] and one in North 
America[13]. The organ allocation mechanisms vary 
by region. Furthermore there were differences in the 
patient populations and surgical philosophies, which 
limit the interpretation of aggregate data. The optimal 
strategy for size matching decisions and thresholds to 
perform a ddLLTx, especially for recipient with restrictive 
lung disease, remains to be defined. Important open 
questions include: (1) Is there a threshold where the 
risk of implanting an oversized full allograft exceeds the 
risks of a ddLLTx and ddLLTx should be recommended? 
(2) When ddLLTx leads to a very undersized lobar 
allograft based on the pTLCratioLobar, is there a threshold 
where the risks of PGD and poor outcomes start to rise 
substantially? and (3) Would the risk of PGD and the 
overall outcome of reasonably matched ddLLTx compare 
to those of full-size allografts if performed routinely in 
elective cases?
In conclusion, ddLLTx is an important and so far 
underutilized surgical option for lung transplant candidates 
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with small pTLC. It is only performed at a few specialized 
centers and frequently performed in high urgency cases. 
Outcome is acuity-driven and is expected to improve as 
more elective cases are done. Systematically using the 
pTLCratio as the size matching tool could help to identify 
sizing thresholds to maximize the risk/benefit balance for 
ddLLTx. 
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Background
Lung transplantation (LTx) is an established therapy for appropriately selected 
patients suffering from end-stage lung disease. Potential LTx-recipients with 
short stature and small thoracic cavities have longer waiting times on the LTx 
list, as donor lungs considered to be size-appropriate are particularly limited. 
Deceased-donor-lobar lung transplantation (ddLLTx) is an important and so 
far underutilized surgical option for lung transplant candidates with small chest 
cavities. The size matching decision for ddLLTx is complex and based on 
varying parameters.
Research frontiers
The best donor-to-recipient size-matching parameter in LTx remains controversial. 
Chest X-ray parameters, calculation of the ratio between donor and recipient 
heights, calculation of the ratio of predicted total lung capacity (pTLC) between 
donor and recipient (pTLCratio) and estimation based on visual inspection in the 
operating room are commonly used strategies. Amongst these the pTLCratio has 
the largest evidence base to support its use. Systematically using the pTLCratio 
as the size matching tool could help to identify sizing thresholds to maximize the 
risk/benefit balance for ddLLTx. 
Innovations and breakthroughs 
In this systematic review the authors’ analyzed all reports on ddLLTx and 
uniformly described size matching using the donor-to-recipient predicted-total 
lung-capacity (pTLC) ratio and summarized reported one-year survival data of 
ddLLTx and conventional-LTx. Nine observational cohort studies reporting on 301 
ddLLTx met the inclusion criteria for systematic review of size matching, and eight 
for describing one-year-survival. The ddLLTx-group was often characterized by 
high acuity; however there was heterogeneity in transplant indications and pre-
operative characteristics between studies. Data to calculate the pTLCratio was 
available for 242 ddLLTx (80%). The mean pTLCratio before lobar resection was 
1.25 ± 0.3 and the transplanted pTLCratio after lobar resection was 0.76 ± 0.2. 
One-year survival in the ddLLTx-group ranged from 50%-100%, compared to 
72%-88% in the conventional-LTx group. In the largest study ddLLTx (n = 138) 
was associated with a lower one-year-survival compared to conventional-LTx (n = 
539) (65.1% vs 84.1%, P < 0.001).
Applications
ddLLTx is an important and so far underutilized surgical option for lung transplant 
candidates with small pTLC. It is only performed at a few specialized centers 
and frequently performed in high urgency cases. Outcome is acuity-driven and 
is expected to improve as more elective cases are done. Systematically using 
the pTLCratio as the size matching tool could help to identify sizing thresholds to 
maximize the risk/benefit balance for ddLLTx. 
Terminology
The technique of deceased donor lobar lung transplantation (ddLLTx) is an 
important surgical option for LTx-candidates with small chest cavities. The lung 
is a special organ that allows parenchyma resections to reduce its size without 
necessarily compromising the functionality of the remaining tissue. Amongst 
other solid organs, this remarkable feature is only shared by the liver, not by the 
heart or the kidneys and split liver transplants have already been established as 
a reliable tool to increase the donor pool for children.
Peer-review
The authors have prepared an excellent review of the literature concerning 
the lobar transplantation (LTx). That technique is one of the new possibility for 
improving the number of LTx and to save a larger number of patients in very 
poor respiratory condition. The work is absolutely important and deserves a 
priority publication.
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